Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1NSCLC 1Myelodysplastic Syndromes 1Mucopolysaccharidosis I 1Metastatic Castration-resistant Prostate Cancer 1Metabolism, Inborn Errors 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunologic Deficiency Syndromes 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hemoglobinopathies 1Graft vs Host Disease 1Disease Progression 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Clinical Trials, Phase I as Topic × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡